Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
CONTEXT AND OBJECTIVE: One of the treatments for hyperinsulinemic hyperandrogenism in nonobese women is combined androgen receptor blockade (with flutamide; Flu), insulin sensitization (with metformin; Met) plus an estroprogestagen contraceptive. We tested whether adding low-dose pioglitazone (Pio; 7.5 mg/d) confers more benefit. SETTING: The study was conducted at a university hospital. STUDY POPULATION AND DESIGN: This double-blind study enrolled 38 young women with hyperinsulinemic hyperandrogenism [mean body mass index (BMI) 24 kg/m(2)], all of whom started on Flu (62.5 mg/d) and Met (850 mg/d) plus a transdermal estroprogestagen, each for 21 of 28 d over 6 months. Patients were randomly assigned to receive, in addition, placebo (n=19) or Pio (n=19; 7.5 mg/d) for the same 21 of 28 d over 6 months. MAIN OUTCOMES: BMI, waist to hip ratio, hirsutism score, fasting endocrine-metabolic markers, body composition, abdominal fat (visceral vs. sc), and carotid intima-media thickness were measured at study start and after 6 months. RESULTS: PioFluMet reduced intima-media thickness more than FluMet and lowered glucose, IGF-I, and C-reactive protein more as well as the ratio of low-density lipoprotein to high-density lipoprotein cholesterol and the ratio of neutrophils to lymphocytes. PioFluMet treatment was followed by a leaner body composition and a loss of visceral fat (both P < 0.001). In the total group, the changes included not only decreases in waist to hip ratio, hirsutism score, and testosterone (all P < 0.001) but also minor drops in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, and lactate dehydrogenase (all P < 0.005), indicating absence of hepatotoxicity; BMI remained unchanged. Clinical side effects were not detected. CONCLUSION: In this proof-of-concept study, addition of Pio to FluMet plus an estroprogestagen led to improvements in the endocrine-metabolic condition, in low-grade inflammation, in total and visceral adiposity, and in markers of cardiovascular health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Ehrmann, D. A., Liljenquist, D. R., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1329 · Cited by 703
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data
NEW, M. I., LORENZEN, F., LERNER, A. J., KOHN, B., OBERFIELD, S. E., POLLACK, M. S., DUPONT, B., STONER, E., LEVY, D. J., PANG, S., et al. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-320 · Cited by 624 · cited 1×
“Exclusion criteria were evidence of thyroid dysfunction, Cushing’s syndrome or hyperprolactinemia; glucose intolerance (15); personal history of diabetes mellitus; late-onset adrenal hyperplasia (16, 17); anemia; abnormal serum electrolytes; abnormal screening results for liver or kidney function; or abnormal echocard…”
BackgroundGambineri, A., Patton, L., Vaccina, A., Cacciari, M., Morselli-Labate, A. M., Cavazza, C., Pagotto, U., & Pasquali, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2250 · Cited by 221 · cited 3×
“• Combined Therapy for Androgen Excess J Clin Endocrinol Metab, May 2007, 92(5):1710–1714 1711”
BackgroundInfluentialPark, Y.-W., Heymsfield, S., & Gallagher, D. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801982 · Cited by 196 · cited 1×
“Subjects were placed on the platform with arms extended above the head, according to standard imaging procedures (23).”
MethodMermejo, L. M., Elias, L. L. K., Marui, S., Moreira, A. C., Mendonca, B. B., & de Castro, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1552 · Cited by 91 · cited 1×
“Exclusion criteria were evidence of thyroid dysfunction, Cushing’s syndrome or hyperprolactinemia; glucose intolerance (15); personal history of diabetes mellitus; late-onset adrenal hyperplasia (16, 17); anemia; abnormal serum electrolytes; abnormal screening results for liver or kidney function; or abnormal echocard…”
BackgroundBERRIA, R., GASTALDELLI, A., LUCIDI, S., BELFORT, R., DEFILIPPIS, E., EASTON, C., BRYTZKI, R., CUSI, K., JOVANOVIC, L., & DEFRONZO, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.014 · Cited by 33 · cited 1×
“These falls in hematocrit are thought to be mainly attributable to concomitant drops in circulating androgens and thus in androgen-driven hematopoiesis (37).”
Background
Cited by
Adipose Tissue Dysfunction in Polycystic Ovary Syndrome
Bril, F., Ezeh, U., Amiri, M., Hatoum, S., Pace, L., Chen, Y.-H., Bertrand, F., Gower, B., & Azziz, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad356 · Cited by 123
Clinical spectrum of premature pubarche: Links to metabolic syndrome and ovarian hyperandrogenism
Ibáñez, L., Díaz, R., López-Bermejo, A., & Marcos, M. V. (2009) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9096-y · Cited by 106
Self-citationInterventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65
Luque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
Hyperinsulinaemic androgen excess in adolescent girls
Ibáñez, L., Ong, K. K., López-Bermejo, A., Dunger, D. B., & de Zegher, F. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.58 · Cited by 56
Self-citation
Metadata
- Authors
- Ibáñez, L., López-Bermejo, A., del Rio, L., Enríquez, G., Valls, C., & de Zegher, F.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-05-01
- Volume
- 92
- Issue
- 5
- Pages
- 1710-1714
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2148914139
- Cited by
- 51
- References
- 7
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.